Inovio Pharmaceuticals Inc vs MiniMed Group Inc. Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while MiniMed Group Inc. Common Stock trades at $19.71 (market cap $5.57B). The key difference: MiniMed Group Inc. Common Stock is far larger — about 49.6× Inovio Pharmaceuticals Inc's market cap, and MiniMed Group Inc. Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and MiniMed Group Inc. Common Stock for 1 Days on average.
| INO | MMED | |
|---|---|---|
Market Cap | $112.19M | $5.57B |
Volume | 3,201,278 | 23,336,073 |
Sector | Health | Health |
52-Week High | $2.65 | $23.84 |
52-Week Low | $0.66 | $10.80 |
Typical Hold Time | 43 Days | 1 Days |
Enterprise Value | $83.51M | $5.37B |
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →